{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:26:29Z","timestamp":1789424789371,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06184-8","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T20:19:24Z","timestamp":1748031564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Salbutamol in 5q spinal muscular atrophy: a systematic review and meta-analysis of efficacy and safety"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5983-6762","authenticated-orcid":false,"given":"Xiaodong","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wengao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"6184_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022) Spinal muscular atrophy. Nat Rev Dis Primers 8:52","journal-title":"Nat Rev Dis Primers"},{"key":"6184_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","volume":"44","author":"B Wirth","year":"2021","unstructured":"Wirth B (2021) Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci 44:306\u2013322","journal-title":"Trends Neurosci"},{"key":"6184_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N (2020) Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet 21:231\u2013261","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"6184_CR4","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","volume":"2","author":"H Chaytow","year":"2021","unstructured":"Chaytow H, Faller KME, Huang YT, Gillingwater TH (2021) Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med 2:100346","journal-title":"Cell Rep Med"},{"key":"6184_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs 77:473\u2013479","journal-title":"Drugs"},{"key":"6184_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM (2019) Onasemnogene Abeparvovec: first global approval. Drugs 79:1255\u20131262","journal-title":"Drugs"},{"key":"6184_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, Mercuri E, Rose K, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Seabrook T, Fontoura P, Servais L (2021) Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 384:915\u2013923","journal-title":"N Engl J Med"},{"key":"6184_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jmg.2007.051177","volume":"45","author":"C Angelozzi","year":"2008","unstructured":"Angelozzi C, Borgo F, Tiziano FD, Martella A, Neri G, Brahe C (2008) Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 45:29\u201331","journal-title":"J Med Genet"},{"key":"6184_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2165\/00003495-198938010-00004","volume":"38","author":"AH Price","year":"1989","unstructured":"Price AH, Clissold SP (1989) Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs 38:77\u2013122","journal-title":"Drugs"},{"key":"6184_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1042\/cs0830615","volume":"83","author":"L Martineau","year":"1992","unstructured":"Martineau L, Horan MA, Rothwell NJ, Little RA (1992) Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci (Lond) 83:615\u2013621","journal-title":"Clin Sci (Lond)"},{"key":"6184_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1249\/00005768-199511000-00002","volume":"27","author":"JF Caruso","year":"1995","unstructured":"Caruso JF, Signorile JF, Perry AC, Leblanc B, Williams R, Clark M, Bamman MM (1995) The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 27:1471\u20131476","journal-title":"Med Sci Sports Exerc"},{"key":"6184_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00007256-200737020-00001","volume":"37","author":"W Kindermann","year":"2007","unstructured":"Kindermann W (2007) Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes? Sports Med 37:95\u2013102","journal-title":"Sports Med"},{"key":"6184_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mus.22176","volume":"44","author":"T Liewluck","year":"2011","unstructured":"Liewluck T, Selcen D, Engel AG (2011) Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 44:789\u2013794","journal-title":"Muscle Nerve"},{"key":"6184_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.nmd.2012.11.004","volume":"23","author":"G Burke","year":"2013","unstructured":"Burke G, Hiscock A, Klein A, Niks EH, Main M, Manzur AY, Ng J, de Vile C, Muntoni F, Beeson D, Robb S (2013) Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 23:170\u2013175","journal-title":"Neuromuscul Disord"},{"key":"6184_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jns.2013.05.017","volume":"331","author":"PJ Lorenzoni","year":"2013","unstructured":"Lorenzoni PJ, Scola RH, Kay CS, Filla L, Miranda AP, Pinheiro JM, Chaouch A, Lochm\u00fcller H, Werneck LC (2013) Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation. J Neurol Sci 331:155\u2013157","journal-title":"J Neurol Sci"},{"key":"6184_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1212\/WNL.0000000000001952","volume":"85","author":"PM Rodr\u00edguez Cruz","year":"2015","unstructured":"Rodr\u00edguez Cruz PM, Palace J, Ramjattan H, Jayawant S, Robb SA, Beeson D (2015) Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes. Neurology 85:1043\u20131047","journal-title":"Neurology"},{"key":"6184_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0140-6736(95)90869-2","volume":"345","author":"S Braun","year":"1995","unstructured":"Braun S, Croizat B, Lagrange MC, Warter JM, Poindron P (1995) Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet 345:694\u2013695","journal-title":"Lancet"},{"key":"6184_CR18","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","volume":"17","author":"S Kariya","year":"2008","unstructured":"Kariya S, Park GH, Maeno-Hikichi Y, Leykekhman O, Lutz C, Arkovitz MS, Landmesser LT, Monani UR (2008) Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 17:2552\u20132569","journal-title":"Hum Mol Genet"},{"key":"6184_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/hmg\/ddm367","volume":"17","author":"LM Murray","year":"2008","unstructured":"Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH (2008) Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet 17:949\u2013962","journal-title":"Hum Mol Genet"},{"key":"6184_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","volume":"29","author":"L Kong","year":"2009","unstructured":"Kong L, Wang X, Choe DW, Polley M, Burnett BG, Bosch-Marc\u00e9 M, Griffin JW, Rich MM, Sumner CJ (2009) Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci 29:842\u2013851","journal-title":"J Neurosci"},{"key":"6184_CR21","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","volume":"79","author":"RI Wadman","year":"2012","unstructured":"Wadman RI, Vrancken AF, van den Berg LH, van der Pol WL (2012) Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology 79:2050\u20132055","journal-title":"Neurology"},{"key":"6184_CR22","doi-asserted-by":"publisher","first-page":"e0165818","DOI":"10.1371\/journal.pone.0165818","volume":"11","author":"A LoMauro","year":"2016","unstructured":"LoMauro A, Aliverti A, Mastella C, Arnoldi MT, Banfi P, Baranello G (2016) Spontaneous breathing pattern as respiratory functional outcome in children with spinal muscular atrophy (SMA). PLoS ONE 11:e0165818","journal-title":"PLoS ONE"},{"key":"6184_CR23","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"6184_CR24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"6184_CR25","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch\u00fcnemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"6184_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru C, Munn Z, Stephenson M, Aromataris E (2015) Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc 13:196\u2013207","journal-title":"Int J Evid Based Healthc"},{"key":"6184_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/WNL.59.4.609","volume":"59","author":"M Kinali","year":"2002","unstructured":"Kinali M, Mercuri E, Main M, De Biasia F, Karatza A, Higgins R, Banks LM, Manzur AY, Muntoni F (2002) Pilot trial of albuterol in spinal muscular atrophy. Neurology 59:609\u2013610","journal-title":"Neurology"},{"key":"6184_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","volume":"18","author":"M Pane","year":"2008","unstructured":"Pane M, Staccioll S, Messina S, D\u2019Arnico A, Pelliccioni M, Mazzone ES, Cuttini M, Alfieri P, Battinif R, Main M, Muntoni F, Bertini E, Villanova M, Mercuri E (2008) Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 18:536\u2013540","journal-title":"Neuromuscul Disord"},{"key":"6184_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmg.2010.080366","volume":"47","author":"FD Tiziano","year":"2010","unstructured":"Tiziano FD, Lomastro R, Pinto AM, Messina S, D\u2019Amico A, Fiori S, Angelozzi C, Pane M, Mercuri E, Bertini E, Neri G, Brahe C (2010) Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet 47:856\u2013858","journal-title":"J Med Genet"},{"key":"6184_CR30","doi-asserted-by":"publisher","first-page":"A41","DOI":"10.1136\/adc.2011.212563.91","volume":"96","author":"SC Tan","year":"2011","unstructured":"Tan SC, Williams AN (2011) Oral salbutamol in 2 wheelchair bound cases of SMA type II. Arch Dis Child 96:A41\u2013A42","journal-title":"Arch Dis Child"},{"key":"6184_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","volume":"73","author":"S Khirani","year":"2017","unstructured":"Khirani S, Dabaj I, Amaddeo A, Arroyo JO, Ropers J, Tirolien S, Coudert V, Estournet B, Fauroux B, Quijano-Roy S (2017) Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy. Pediatr Neurol 73:78\u201387","journal-title":"Pediatr Neurol"},{"key":"6184_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","volume":"29","author":"AL Frongia","year":"2019","unstructured":"Frongia AL, Natera-de Benito D, Ortez C, Alarcon M, Borras A, Medin J, Vigo M, Padros N, Moya O, Armas J, Carrera-Garcia L, Exposito-Escudero J, Cuadras D, Bernal S, Martorell L, Colomer J, Nascimento A (2019) Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II. Neuromuscul Disord 29:517\u2013524","journal-title":"Neuromuscul Disord"},{"key":"6184_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","volume":"56","author":"FD Tiziano","year":"2019","unstructured":"Tiziano FD, Lomastro R, Abiusi E, Pasanisi MB, Di Pietro L, Fiori S, Baranello G, Angelini C, Soraru G, Gaiani A, Mongini T, Vercelli L, Mercuri E, Vasco G, Pane M, Vita G, Vita G, Messina S, Petillo R, Passamano L, Politano L, Campanella A, Mantegazza R, Morandi L (2019) Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. J Med Genet 56:293\u2013300","journal-title":"J Med Genet"},{"key":"6184_CR34","doi-asserted-by":"crossref","unstructured":"Feng Y, Jin J, Chen T, Wang J, Jiang Y, Gao F, Mao S (2023) Efficacy and safety of salbutamol in treatment of children with later-onset spinal muscular atrophy. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences 52:714\u2013720","DOI":"10.3724\/zdxbyxb-2023-0463"},{"key":"6184_CR35","first-page":"1402","volume":"50","author":"JT Kissel","year":"1998","unstructured":"Kissel JT, McDermott MP, Natarajan R, Mendell JR, Pandya S, King WM, Griggs RC, Tawil R (1998) Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group Neurology 50:1402\u20131406","journal-title":"FSH-DY Group Neurology"},{"key":"6184_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/01.WNL.0000118530.71646.0F","volume":"62","author":"EG Fowler","year":"2004","unstructured":"Fowler EG, Graves MC, Wetzel GT, Spencer MJ (2004) Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology 62:1006\u20131008","journal-title":"Neurology"},{"key":"6184_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1212\/01.WNL.0000287070.00149.a9","volume":"70","author":"CL Skura","year":"2008","unstructured":"Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ (2008) Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 70:137\u2013143","journal-title":"Neurology"},{"key":"6184_CR38","first-page":"e39903","volume":"15","author":"AS Aguirre","year":"2023","unstructured":"Aguirre AS, Astudillo Moncayo OM, Mosquera J, Muyolema Arce VE, Gallegos C, Ortiz JF, Andrade AF, O\u00f1a S, Buj MJ (2023) Treatment of facioscapulohumeral muscular dystrophy (FSHD): a systematic review. Cureus 15:e39903","journal-title":"Cureus"},{"key":"6184_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.nmd.2018.07.013","volume":"28","author":"MC Pera","year":"2018","unstructured":"Pera MC, Luigetti M, Sivo S, Lapenta L, Granata G, Antonaci L, Coratti G, Forcina N, Pane M, Mercuri E (2018) Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? Neuromuscul Disord 28:863\u2013864","journal-title":"Neuromuscul Disord"},{"key":"6184_CR40","first-page":"S101","volume":"257","author":"P De Queiroz","year":"2010","unstructured":"De Queiroz P, Campos Araujo A (2010) Long-term open salbutamol trial in spinal muscular atrophy. J Neurol 257:S101","journal-title":"J Neurol"},{"key":"6184_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/mus.25102","volume":"54","author":"AM Giovannetti","year":"2016","unstructured":"Giovannetti AM, Pasanisi MB, \u010cerniauskait\u0117 M, Bussolino C, Leonardi M, Morandi L (2016) Perceived efficacy of salbutamol by persons with spinal muscular atrophy: a mixed methods study. Muscle Nerve 54:843\u2013849","journal-title":"Muscle Nerve"},{"key":"6184_CR42","first-page":"S301","volume":"27","author":"C Bautista","year":"2017","unstructured":"Bautista C (2017) Usefulness of myocardial strain imaging in spinal muscular atrophy. Cardiol Young 27:S301","journal-title":"Cardiol Young"},{"key":"6184_CR43","doi-asserted-by":"publisher","first-page":"e115473","DOI":"10.1371\/journal.pone.0115473","volume":"9","author":"SG Mack","year":"2014","unstructured":"Mack SG, Cook DJ, Dhurjati P, Butchbach ME (2014) Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy. PLoS ONE 9:e115473","journal-title":"PLoS ONE"},{"key":"6184_CR44","first-page":"351","volume":"4","author":"NIF Harahap","year":"2015","unstructured":"Harahap NIF, Nurputra DK, Ar Rochmah M, Shima A, Morisada N, Takarada T, Takeuchi A, Tohyama Y, Yanagisawa S, Nishio H (2015) Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells. Biochem Biophys Rep 4:351\u2013356","journal-title":"Biochem Biophys Rep"},{"key":"6184_CR45","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1111\/sms.12312","volume":"25","author":"N Decorte","year":"2015","unstructured":"Decorte N, Lamalle L, Carlier PG, Giacomini E, Guinot M, Levy P, Verges S, Wuyam B (2015) Impact of salbutamol on muscle metabolism assessed by 31P NMR spectroscopy. Scand J Med Sci Sports 25:e267\u2013273","journal-title":"Scand J Med Sci Sports"},{"key":"6184_CR46","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1474-4422(19)30405-3","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Di Filippo M (2019) Serum neurofilament light chain as a preclinical marker of neurodegeneration. Lancet Neurol 18:1070\u20131071","journal-title":"Lancet Neurol"},{"key":"6184_CR47","first-page":"S68","volume":"8","author":"L Carrera","year":"2021","unstructured":"Carrera L, Exp\u00f3sito J, Natera D, Medina J, Vigo M, Moya O, Roca S, Padros N, S\u00e1ez V, Muchart J, Jim\u00e9nez C, Colomer J, Ortez C, Nascimento A (2021) Usefulness of natural history trajectories in the interpretation of nusinersen treatment effect in SMA patients. Journal of Neuromuscular Diseases 8:S68\u2013S69","journal-title":"Journal of Neuromuscular Diseases"},{"key":"6184_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton G, Gillingwater TH (2013) Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 19:40\u201350","journal-title":"Trends Mol Med"},{"key":"6184_CR49","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1007\/s00431-023-04928-y","volume":"182","author":"R Luciano","year":"2023","unstructured":"Luciano R, Romeo DM, Mancini G, Sivo S, Dolci C, Velli C, Turriziani Colonna A, Vento G, Romagnoli C, Mercuri EM (2023) Response to the comment on: \u201cneurological development and iron supplementation in healthy late-preterm neonates: a randomized double-blind controlled trial.\u201d Eur J Pediatr 182:2933\u20132934","journal-title":"Eur J Pediatr"},{"key":"6184_CR50","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1007\/s00431-024-05735-9","volume":"183","author":"M Pane","year":"2024","unstructured":"Pane M, Stanca G, Coratti G, Amico A, Sansone VA, Berti B, Fanelli L, Albamonte E, Cefaro CA, Cerchiari A, Catteruccia M, De Sanctis R, Leone D, Palermo C, Buchignani B, Onesimo R, Kuczynska EM, Tosi M, Pera MC, Bravetti C, Tiziano FD, Bertini E, Mercuri E (2024) Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study. Eur J Pediatr 183:4735\u20134745","journal-title":"Eur J Pediatr"},{"key":"6184_CR51","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","volume":"14","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Talbot K, Gillingwater TH (2018) Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol 14:214\u2013224","journal-title":"Nat Rev Neurol"},{"key":"6184_CR52","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s00415-023-11787-y","volume":"270","author":"HS Lapp","year":"2023","unstructured":"Lapp HS, Freigang M, Hagenacker T, Weiler M, Wurster CD, G\u00fcnther R (2023) Biomarkers in 5q-associated spinal muscular atrophy-a narrative review. J Neurol 270:4157\u20134178","journal-title":"J Neurol"},{"key":"6184_CR53","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","volume":"23","author":"CRR Alves","year":"2021","unstructured":"Alves CRR, Petrillo M, Spellman R, Garner R, Zhang R, Kiefer M, Simeone S, Sohn J, Eichelberger EJ, Rodrigues E, Arruda EA, Townsend EL, Farwell W, Swoboda KJ (2021) Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series. Mol Ther Methods Clin Dev 23:524\u2013538","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6184_CR54","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4103\/NRR.NRR-D-24-00067","volume":"20","author":"X Xing","year":"2025","unstructured":"Xing X, Liu X, Li X, Li M, Wu X, Huang X, Xu A, Liu Y, Zhang J (2025) Insights into spinal muscular atrophy from molecular biomarkers. Neural Regen Res 20:1849\u20131863","journal-title":"Neural Regen Res"},{"key":"6184_CR55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Qian Y, Sejersen T (2018) Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 28:197\u2013207","journal-title":"Neuromuscul Disord"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06184-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:05:13Z","timestamp":1749467113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06184-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["6184"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06184-8","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent and ethical approval were not sought for this paper because it included no direct interaction with human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"358"}}